177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements

Published:2021-06-27 Issue:8 Volume:35 Page:861-870
ISSN:0914-7187
Container-title:Annals of Nuclear Medicine
language:en
Short-container-title:Ann Nucl Med

Author:

Cao Jianpeng,Chen Yue,Hu Mei,Zhang Wei

Funder

Sichuan Province Science and Technology Support Program

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12149-021-01649-w.pdf

Reference100 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

2. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151–4.

3. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194(6):1537–47.

4. Tateishi U. Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer. Jpn J Clin Oncol. 2020;50(4):349–56.

5. Rybalov M, Ananias HJ, Hoving HD, Van der Poel HG, Rosati S, De Jong IJ. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci. 2014;15(4):6046–61.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PLA tissue-engineered scaffolds loaded with sustained-release active substance chitosan nanoparticles: Modeling BSA-bFGF as the active substance;International Journal of Biological Macromolecules;2024-08

2. Current clinical application of lutetium‑177 in solid tumors (Review);Experimental and Therapeutic Medicine;2024-03-26

3. Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer;Molecules;2023-05-11

4. Lutetium Lu 177 vipivotide tetraxetan for prostate cancer;Drugs of Today;2023-01

5. From Therapy Resistance to Targeted Therapies in Prostate Cancer;Frontiers in Oncology;2022-05-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3